MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Other Events

ME Staff 8-k
-
0
MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Other Events

MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Other Events
Item 8.01 Other Events.

On June 11, 2019, MiMedx Group, Inc. (the “Company”) issued a press release announcing that Institutional Shareholder Services (“ISS”) and Egan-Jones Proxy Services (“Egan-Jones”), leading independent proxy advisory firms, have recommended Company shareholders vote “FOR” the Company’s three director nominees, K. Todd Newton, Dr. Kathleen Behrens Wilsey and Timothy R. Wright on the BLUE proxy card in connection with the Company’s 2018 annual meeting of shareholders to be held on June 17, 2019. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1    Press release of MiMedx Group, Inc., dated June 11, 2019.

2


MIMEDX GROUP, INC. Exhibit
EX-99.1 2 d764452dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Leading Independent Proxy Advisory Firms ISS and Egan-Jones Recommend That MiMedx Shareholders Vote the BLUE Card “FOR” All Three of the Company’s Director Nominees ISS Recommends Shareholders Vote “AGAINST” the Petit Group’s Shareholder Proposals ISS Recommends Shareholders Do Not Vote the White Card MARIETTA,…
To view the full exhibit click here

About MIMEDX GROUP, INC. (NASDAQ:MDXG)

MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.